Biophytis announces the design of its phase 2 OBA clinical study in obesity

14 May 2024 07:00 CEST

Subscribe
Issuer

BIOPHYTIS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1253637_2024_05_14_PR_OBA_phase_2_design.pdf

Source

Biophytis

Provider

Les Echos

Company Name

BIOPHYTIS

ISIN

FR001400OLP5

Symbol

ALBPS

Market

Euronext Growth

Attachments

  • Original Link
  • Permalink

Disclaimer

Biophytis SA published this content on 14 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 May 2024 05:09:41 UTC.